Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

BioMarin Pharmaceutical Inc. has a one year low of $60.63 and a one year high of $94.85. The company has a market capitalization of $12.55 billion, a P/E ratio of 39.44, a price-to-earnings-growth ...

BioMarin Pharmaceutical has a twelve month low of $60.63 and a twelve month high of $94.85. The company has a market capitalization of $12.55 billion, a price-to-earnings ratio of 39.44, a PEG ...

Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended December 2024. While this widely-known ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioMarin Pharmaceutical has made a couple of appointments aimed at boosting its pipeline, both internally and externally, with C-suite appointments in charge of R&D and business development.

The sweeping changes introduced by new BioMarin chief executive Alexander Hardy continue apace, with a second round of layoffs that will cut another 225 positions from its total headcount.